pharmacy-biopharma-2017-posters-accepted-abstracts

Page 60

conferenceseries

.com

Volume 9, Issue 5 (Suppl)

J Bioequiv Availab, an open access journal

ISSN: 0975-0851

Pharmacy & Biopharma 2017

August 31-September 01, 2017 Philadelphia, USA

August 31-September 01, 2017 Philadelphia, USA

International Conference on

Biopharmaceutics and Biologic Drugs

International Pharmacy Conference

J Bioequiv Availab 2017, 9:5 (Suppl)

DOI: 10.4172/0975-0851-C1-031

Nanoparticles: Anovel approach to drug development, targeting and therapeutic monitoring

Douglas Taylor

Harrisburg University, USA

Statement of the Problem:

Currently, for most cancers, diagnostic tests are too expensive and invasive; primarily detect late-

stage cancers exhibit too many false negatives/positives to be reliably used. Traditional tissue biopsies provide limited value due

to access and availability of samples. Further, cancers that have spread often differ from the primary and tumor cells change in

response to treatment. Based on these heterogeneities, traditional biopsies can only provide a limited window into the dynamic

genetic and translational changes occurring in tumors, resulting in an ineffective view of tumor progression and metastasis.

Methodology & Theoretical Orientation:

Liquid biopsies, or blood-sample tests can generate actionable information by

analyzing circulating components released from the tumor. The most common version of the liquid biopsy comprises either

circulating tumor cells (CTC) or fragments of tumor cell-derived DNA (cell-free DNA or cfDNA). Since CTCs are markers of

metastatic disease, they have limited application for initial diagnosis or identification of early stage disease. cfDNA is generated

from necrosis and apoptosis and are thus the product of cell death, from both normal and tumor cells. Analysis of cfDNA

provides limited information about tumor cells not affected by specific therapies. In contrast, using our proprietary technology,

it is now possible to enrich for circulating exosomes (50-200 nm vesicles), released specifically by tumor cells.

Findings:

From these cancer specific exosomes, the transcriptome and proteome of the tumor cells can be defined. By

detecting and quantifying genomic alterations reflected in tumor exosomes, these can provide real-time information on

tumor progression, therapeutic targets and treatment effectiveness. We have developed an IVD cancer platform based on our

discovery and characterization of exosomes derived from biofluids, including blood, saliva, cerebrospinal fluid and urine.

These exosomes mirror protein and RNA components present in the tumor cell that released them.

Conclusion & Significance:

Analysis of proteins and RNA cargoes of exosomes derived specifically from the tumor provides

critical information in identifying and monitoring tumor type and stage, as well as predicting and monitoring responses to

therapy and targets for therapy.